Recently, a small molecule ULK1/2 inhibitor DCC-3116 was designed to inhibit autophagy in cancer cells and is under clinical trials in patients with advanced or metastatic solid tumors with RAS/mitogen activated protein kinase (MAPK) pathway mutation (ClinicalTrials.gov, NCT04892017, accessed on 20 December 2022). The gene discussed is DCC; the disease is cancer.